Richard A Md Miller has bought CRVS on 16 days since May 2016

Richard A. Miller, M.D., is a physician-scientist and biotechnology executive who serves as President and Chief Executive Officer of Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on targeted therapies for cancer and immune diseases.( He co-founded Corvus in 2014 and has also been its Chairman, leading development of novel agents such as the ITK inhibitor soquelitinib for T‑cell–mediated conditions.( A board-certified oncologist and Adjunct Clinical Professor of Medicine (oncology) at Stanford University Medical Center, Miller has more than 25 years of experience in drug development and has been recognized with honors including the UC Drug Discovery Consortium’s Drug Hunter Award and a Distinguished Alumni Award from SUNY Downstate Health Sciences University.(

Before Corvus, Miller co-founded several influential biotechnology companies, notably IDEC Corporation and Pharmacyclics, where he played instrumental roles in the discovery and development of rituximab (Rituxan) and ibrutinib (Imbruvica), both multi‑billion‑dollar therapies for lymphoma and related conditions.( He has held multiple C‑suite leadership positions across public and private biotech firms and has combined executive responsibilities with ongoing academic and clinical engagement at institutions such as Stanford.( Miller earned his M.D. summa cum laude from the State University of New York Medical School (SUNY Downstate), and his career has been characterized by integrating oncology, immunology, and biotechnology to advance new treatments for patients with difficult‑to‑treat cancers and immune diseases.(

Written by Perplexity from public sources.